Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis

Danish Medical Bulletin

Volumn 58, Issue 11, 2011, Pages

  Sørensen, Sofie Sølvsten ^a   Mosgaard, Berit Jul ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; COLON CANCER; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; PANCREAS CANCER; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UTERUS CANCER; BLOOD; DIFFERENTIAL DIAGNOSIS; OVARY TUMOR;

CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 81155135363     PISSN: None     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tingulstad S, Hagen B, Skjeldestad FE et al. The risk-of-malignancy index to evaluate potential cancers in local hospitals. Obstet Gynecol 1999;93:448-52.
2. Van Trappen PO, Rufford BD, Mills TD et al. Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gyn Caner 2007;17:61-7.
3. Lewis MR, Deavers MT, Silva EG et al. Ovarian involvement by metastatic colorectal adenocarcinomas, still a diagnostic challenge. Am J Surg Pathol 2006;30:177-84.
4. Lewis MR, Euscher ED, Deavers MT et al. Metastatic colorectal adenocarcinoma involving the ovary with increased serum CA125: A potential diagnostic pifall. Gyn Onc 2007;105:395-8.
5. Jacobs I, Oram D, Fairbanks J et al. A risk of malignany index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-99.
6. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.
7. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.
8. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of literature. Hum Reprod 1989;4:1-12.
9. Høgdall EV, Christensen L, Kjaer SK et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From the Danish MALOVA ovarian cancer study. Gyn Onc 2007;104:508-15.
10. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 2009;100:195-9.
11. Kim DY, Kim HR, Shim JH et al. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol 2000;74:185-92.
12. Høgdall EV, Christensen L, Kjaer SK et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish MALOVA ovarian cancer study. Pathology 2008;40:487-92.
13. Tholander B, Taube A, Lindgren A et al. Pretreatment serum levels of CA125, carcinoemryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinomas: influence of histological type, grade of differentiation, and clinical stage of disease. Gyn Onc 1990;3:26-33.
14. Yabushita H, Masuda T, Ogawa A et al. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer. Gyn Onc 1988;29:66-75.
15. Wu JT, Miya T, Knight JA et al. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by the use of the ratio of CA 125 to carcinoembryonic antigen. Clin Chem 1988;34:1853-7.
16. Buamah PK, Rake MO, Drake SR et al. Serum CA12-5 concentrations and CA12-5/CEA ratios in patients with epithelial ovarian cancer. J Surg Oncol 1990;44:97-9.
17. Yedema CA, Kenemans P, Wobbes T et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13:18-26.